抗VEGF玻璃体腔注射后视网膜脱离风险的系统综述与荟萃分析
9项研究荟萃显示孔源性视网膜脱离的每次注射汇总风险为0.012%(95%CI 0.009-0.015%),相当于每8675次注射1例;眼水平风险为0.08%(95%CI 0.02-0.31%),约每1250只眼1例。结论认为证据确定性低,但孔源性视网膜脱离不常见,眼水平风险对长期治疗患者更具参考意义。
要点
- 抗VEGF注射后孔源性视网膜脱离的每次注射汇总风险为0.012%(约1/8675次注射)。
- 眼水平孔源性视网膜脱离风险为0.08%(约1/1250只眼),不确定性更宽但更贴近长期治疗患者。
- 一项严重增殖性糖尿病视网膜病变研究报道牵拉性视网膜脱离风险为3.6%(约1/28次注射)。
核心结论
- 低确定性证据表明抗VEGF玻璃体腔注射后孔源性视网膜脱离不常见,每次注射风险为0.012%(95%CI 0.009-0.015%)。
- 眼水平风险为0.08%(95%CI 0.02-0.31%),不确定性更宽,但对长期治疗患者更具参考意义。
研究设计与样本
- 系统综述与荟萃分析,遵循PRISMA指南(PROSPERO注册号CRD420251175527)。
- 检索MEDLINE、Embase和Cochrane CENTRAL数据库,检索时间从建库至2026年1月18日。
- 纳入报告抗VEGF玻璃体腔注射后视网膜脱离风险的研究,适应症包括新生血管性年龄相关性黄斑变性、糖尿病黄斑水肿、视网膜静脉阻塞所致黄斑水肿、增殖性糖尿病视网膜病变或近视性脉络膜新生血管。
- 采用随机效应单臂比例荟萃分析,使用广义线性混合模型生成每次注射和每只眼的汇总风险估计。
主要发现
- 术后≤90天的急性期敏感性分析显示孔源性视网膜脱离风险为0.013%(95%CI 0.010-0.016%,I²=36.8%),约每7692次注射1例。
- 眼水平敏感性分析显示每只眼风险为0.08%(95%CI 0.02-0.31%,I²=66.7%),约每1250只眼1例。
- 一项评估严重增殖性糖尿病视网膜病变的研究报道牵拉性视网膜脱离风险为3.6%(95%CI 2.3-5.2%),约每28次注射1例,可能反映疾病特异性纤维血管收缩。
临床怎么用
- 临床医生可在知情同意时引用每次注射孔源性视网膜脱离风险约0.012%(1/8675)和眼水平风险约0.08%(1/1250)来向患者说明风险。
- 对长期接受抗VEGF治疗的患者,眼水平风险可能比每次注射风险更具参考价值,但需注意汇总数据中每眼平均13.8次注射可能低估真实世界累积暴露。
- 对严重增殖性糖尿病视网膜病变患者,应关注牵拉性视网膜脱离风险(约1/28次注射)这一疾病特异性风险。
局限性
- 证据确定性低。
- 眼水平风险估计的不确定性更宽(95%CI 0.02-0.31%,I²=66.7%)。
- 纳入研究的每眼平均注射次数为13.8次,可能低估真实世界累积暴露。
- 未来研究需纳入眼水平分母并标准化报告视网膜脱离亚型、眼部特征和注射技术,以实现风险分层和识别可修改的操作因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
TOPIC: This systematic review and meta-analysis evaluated the literature-pooled risk of retinal detachment (RD) following intravitreal injection (IVI) of anti-vascular endothelial growth factor (anti-VEGF) agents. CLINICAL RELEVANCE: Intravitreal anti-VEGF injections are the most frequently performed intraocular procedure, with RD remaining a poorly quantified complication. Pooled estimates equip clinicians to contextualize RD risk during informed consent. METHODS: This systematic review and meta-analysis followed PRISMA guidelines (PROSPERO: CRD420251175527). MEDLINE, Embase, and Cochrane CENTRAL were searched from inception to January 18, 2026. Included studies reported RD risk after anti-VEGF IVI for neovascular age-related macular degeneration (nAMD), diabetic macular edema, macular edema from retinal vein occlusion, proliferative diabetic retinopathy, or myopic choroidal neovascularization. Paired reviewers independently extracted data and assessed risk of bias using ROBINS-I and the Joanna Briggs Institute checklist for case series. A random-effects single-arm meta-analysis of proportions using a generalized linear mixed model generated pooled risk estimates per injection and per eye. RESULTS: Twelve studies comprising 834 814 injections and 119 RD events were included. In the meta-analysis of 9 studies (787 849 injections), there were 92 rhegmatogenous RD (RRD) events, with a pooled risk of 0.012% (95% CI [0.009-0.015%], I²: 14.4%), equivalent to 1 in 8675 injections. An acute ≤90-day postprocedural sensitivity analysis yielded a consistent RRD risk of 0.013% (95% CI [0.010-0.016%], I²: 36.8%) (approximately 1 in 7692 injections). An eye-level sensitivity analysis yielded a per-eye risk of 0.08% (95% CI [0.02-0.31%], I²: 66.7%) (approximately 1 in 1250 eyes). Exploratory subgroup analyses showed no differences in RRD risk by injection number (≥100 000 vs <100 000; P = .520), study setting (single-center vs multicenter; P = .258), injection indication (nAMD only vs mixed; P = .061), injection provider (ophthalmologist vs mixed; P = .259), or risk of bias (P = .356). One study evaluating severe PDR reported tractional RD risk as 3.6% (95% CI [2.3-5.2%]) (approximately 1 in 28 injections), likely reflecting disease-specific fibrovascular contraction. CONCLUSION: Low-certainty evidence indicates RRD following anti-VEGF IVI is uncommon, with a per-injection risk of 0.012% (1 in 8675 injections). Per-eye risk was 0.08% (1 in 1250 eyes), which was subject to wider uncertainty but more relevant to patients undergoing long-term treatment; notably, the pooled mean of 13.8 injections per eye in the contributing studies likely underestimates real-world cumulative exposure. Future work should incorporate eye-level denominators and standardized reporting of RD subtypes, ocular characteristics, and injection technique to enable risk stratification and identification of modifiable procedural contributors.
引用
- Mikhail D, Tao BK, Yu P, et al. Risk of Retinal Detachment After Intravitreal Injection of Anti-VEGF: A Systematic Review and Meta-Analysis. Am J Ophthalmol. 2026. PMID: 42219076. doi:10.1016/j.ajo.2026.05.042
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。